Adjuvant I.V. Iron Therapy During Erythropoetin Treatment of Anemic Patients With Lymphoproliferative Disorders.
Status:
Completed
Trial end date:
2005-12-01
Target enrollment:
Participant gender:
Summary
This is a multi-center open label, randomized phase-3 study with stratification according to
diagnosis and baseline serum-EPO level. The correction of mild or moderate anemia and the
effect on iron kinetics by the rHuEPO treatment with or without intravenous iron
supplementation in anemic patients with LPD not receiving antineoplastic therapy will be
studied. The study will be performed according to the ICH-GCP guidelines. In order to be
eligible, the patient must consent in writing that he/she agrees to participate in the study.
The patient recruitment period is estimated to be no longer than 18 months.